Article Text

Download PDFPDF
Rituximab in the spondyloarthropathies: data of eight patients followed up in the French Autoimmunity and Rituximab (AIR) registry
  1. G Nocturne1,
  2. M Dougados2,
  3. A Constantin3,
  4. C Richez4,
  5. J Sellam5,
  6. A Simon6,
  7. D Wendling7,
  8. X Mariette1,
  9. J-E Gottenberg8
  1. 1
    Rhumatologie, Institut Pour la Santé et la Recherche Médicale (INSERM), Université Paris-Sud, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin Bicêtre, Paris, France
  2. 2
    Rhumatologie, Hôpital Cochin, APHP, Paris, France
  3. 3
    Rhumatologie, Hôpital de Toulouse, Toulouse, France
  4. 4
    Rhumatologie, Hôpital de Bordeaux, Bordeaux, France
  5. 5
    Rhumatologie, Hôpital Saint-Antoine, APHP, Paris, France
  6. 6
    Rhumatologie, Hôpital de Limoges, Limoges, France
  7. 7
    Rhumatologie, Hôpital Jean Minjoz, Besançon, France
  8. 8
    Rhumatologie, Université Louis Pasteur, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
  1. Correspondence to Professor X Mariette, Service de Rhumatologie, Hôpital de Bicêtre, 78 rue du Général Leclerc, 94275 Le Kremlin Bicêtre, Paris France; xavier.mariette{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

No data are available regarding the safety and efficacy of B-cell depletion in the spondyloarthropathies (SpA), except for two case reports. One patient with ankylosing spondylitis (AS) was prescribed rituximab (RTX) for lymphoma without any improvement of the AS.1 One patient with psoriatic arthritis responded to RTX.2

The French Autoimmunity and Rituximab (AIR) registry, prospectively collects data on patients treated with RTX on- and off-label for refractory arthritides by their clinicians.3 On 23 February 2009, 1383 patients with rheumatoid arthritis, 93 with systemic lupus erythematosus, 43 with primary Sjögren’s syndrome, 55 with vasculitis, 30 with myositis and 112 with other autoimmune or inflammatory diseases, had been included in AIR registry. Among the last group …

View Full Text


  • Funding The French Society of Rheumatology is the promoter of AIR registry. A restricted grant from Roche was allocated for the first 5 years of the AIR registry.

  • Competing interests None.

  • Ethics approval Ethics committee approval from the AIR registry.

  • Patient consent Patient consent received.

  • Provenance and Peer review Not commissioned; externally peer reviewed.